<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        469-149-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        BIOCAFFCIT
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CAFFEINE CITRATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        398.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Pharmaceutical Solution Industries (PSI)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Pharmaceutical Solution Industries (PSI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 444]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Pharmaceutical Solution Industries (PSI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Pharmaceutical Solution Industries (PSI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N06BC01 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>* Caffeine belongs to a group of medicines known as methylxanthines<br />&bull; It is used in the treatment of interrupted breathing in premature babies (primary apnoea of premature newborns).<br />These short periods when premature babies stop breathing are due to the babyʼs breathing centers not being fully developed. This medicine has been shown to reduce the number of episodes of interrupted breathing in premature newborns.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your baby should not be given Biocaffcit 10mg/ml Solution for Injection<br />&bull; If allergic to caffeine citrate or to any of the other ingredients of this medicine listed in section 6</p><p><strong>Warnings &amp; precautions</strong><br />Talk to your babyʼs doctor before your newborn is given Biocaffcit 10mg/ml Solution for&nbsp;<br />Injection if your baby:<br />&bull; has liver or kidney disease<br />&bull; has had any unusual heart rhythms detected or heart disease<br />&bull; suffers from seizures<br />&bull; has frequent regurgitation<br />&bull; produces more urine than usual<br />&bull; has a reduced weight gain or food intake<br />&bull; If you (the mother) consumed caffeine prior to delivery</p><p>&nbsp;</p><p><strong>Other medicines and Biocaffcit 10mg/ml solution for injection</strong><br />Tell your babyʼs doctor if your newborn is taking, have recently taken or might take any&nbsp;<br />other medicines.<br />&bull; As with most medicines, Biocaffcit 10mg/ml Solution for Injection may interact with other&nbsp;<br />medicines given at the same time. A premature baby may need many medicines, and any&nbsp;<br />problems with caffeine are likely to be minor, but tell the doctor about any other medication&nbsp;<br />they may not know about, particularly any other medicine (for example theophylline) given&nbsp;<br />to your baby to help it breathe.<br />&bull; Medications containing phenobarbitone or phenytoin, taken by the mother herself to&nbsp;<br />treat epilepsy, may also have an effect on the way the baby reacts to caffeine therapy. If&nbsp;<br />you have been taking treatment for epilepsy during pregnancy, please tell your babyʼs&nbsp;<br />doctor about it.<br />&bull; Doxapram (used to treat breathing difficulties)<br />&bull; Cimetidine (used to treat gastric disease)<br />&bull; Ketoconazole (used to treat fungal infections)<br />&bull; This medicine may increase the risk for serious intestinal disease with bloody stools&nbsp;<br />(necrotizing enterocolitis) when administered with medicines used to treat gastric&nbsp;<br />disease (such as antihistamine H2 receptor blockers or proton-pump inhibitors that&nbsp;<br />reduces gastric acid secretion).</p><p><strong>Pregnancy and breast-feeding</strong><br />If you (the mother) are breast-feeding while your infant is treated with Biocaffcit&nbsp;<br />10mg/ml Solution for Injection, you should not drink coffee or take any other high&nbsp;<br />caffeine product as caffeine passes into breast milk.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Biocaffcit 10mg/ml solution for injection should only be used in a neonatal intensive care&nbsp; unit in which adequate facilities are available for patient surveillance and monitoring.&nbsp;Treatment should be initiated under supervision of a physician experienced in neonatal&nbsp;<br />intensive care.<br />The doctor or nurse will administer Biocaffcit 10mg/ml Solution for Injection into a&nbsp;venous infusion (drip). It can also be equally effective when given by mouth, and all or&nbsp;some of the doses may be given this way when possible. This medicine should not be&nbsp;given by intramuscular injection.</p><p><strong>The exact dose, to be determined by the doctor, depends on each baby&rsquo;s needs and response to the treatment, but will usually be:</strong></p><p>&bull; A starting dose of 20mg/kg of the babyʼs body weight calculated as caffeine citrate (equivalent to caffeine 10mg/kg or 2ml/kg of this solution) if by injection then infused over 30 minutes</p><p>&bull; Followed after 24 hours by a lower daily maintenance dose of 5 to 10mg/kg of the baby&rsquo;s body weight calculated as caffeine citrate (equivalent to caffeine 2.5 to 5mg/kg or 0.5 to 1ml/kg of this solution) if by injection then infused over 10 minutes If your baby fails to respond to the starting dose (after at least 4 hours), the doctor or nurse may give one more additional starter dose, before continuing to the lower maintenance doses.</p><p><strong>Duration of treatment</strong><br />Your babyʼs doctor will decide exactly how long your newborn must continue therapy&nbsp; with Biocaffcit 10mg/ml Solution for Injection. If your baby has 5 to 7 days without&nbsp;apnoea attacks, the doctor will stop treatment. The doctor may decide to check the levels of caffeine in a blood sample as a&nbsp;<br />precaution, or if your baby is not responding to treatment as expected.</p><p><strong>If your baby is given more Biocaffcit 10mg/ml Solution for Injection than they should</strong>&nbsp;If too much caffeine solution is accidentally given to your baby, the side effects described&nbsp;above may become more noticeable. In cases of very high overdosage, fits can also&nbsp;<br />occur. If signs of over-dosage are noticed, please tell the babyʼs doctor immediately. Treatment with Biocaffcit 10mg/ ml Solution for Injection should be stopped immediately&nbsp;<br />and your babyʼs doctor should treat the overdose.<br />If you have any further questions on the use of this medicinal product, ask your babyʼs doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets&nbsp;<br />them. However, it is difficult to distinguish them from frequent complications occurring in&nbsp;<br />premature babies and complications due to the disease.<br />While under treatment with Biocaffcit 10 mg/ml Solution for Injection, your newborn may&nbsp;<br />experience some of the following reactions:<br /><strong>Serious side effects</strong><br />&bull; Serious intestinal disease with bloody stools (necrotising enterocolitis).<br />&bull; Convulsion<br />&bull; Allergic reactions<br />&bull; Bloodstream infection (sepsis)<br /><strong>Other side effects</strong><br /><strong>Common (may affect up to 1 in 10 people)</strong><br />&bull; Cardiac disorders such as fast heart beat (tachycardia)<br />&bull; increased sugar in blood or serum (hyperglycaemia)<br /><strong>Uncommon (may affect up to 1 in 100 people)</strong><br />&bull; Cardiac disorders such as irregular heart beat (arrhythmia)<br /><strong>Not known (frequency cannot be estimated from the available data)</strong><br />&bull; reduced sugar in blood or serum (hypoglycaemia)<br />&bull; Failure to grow<br />&bull; feeding intolerance<br />&bull; Stimulation of central nervous system such as irritability<br />&bull; Nervousness and restlessness<br />&bull; Brain injury<br />&bull; Deafness<br />&bull; Regurgitation<br />&bull; Increase in stomach aspirate<br />&bull; Increase of urine flow<br />&bull; Increase of certain urine components (sodium and calcium)<br />&bull; Changes in blood tests (reduced levels of haemoglobin after prolonged treatment)<br />&bull; reduced thyroid hormone at the start of treatment<br /><strong>Reporting of side effects&nbsp;</strong><br />If your baby gets any side effects, talk to your baby&rsquo;s doctor. This includes any possible&nbsp;<br />side effects not listed in this leaflet.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.&nbsp;<br />Do not store above 30&deg;C.&nbsp;<br />All parenteral solutions must be inspected visually for particulate matter prior to&nbsp;<br />administration. After opening the vial, the medicinal product should be used immediately<br />In case of dilution, the diluted solution could be stored at room temperature for 4 hours.<br />Do not use this medicine after the expiry date which is stated on the label, or if there are&nbsp;<br />any signs of discoloration or clouding of the solution.<br />The expiry date refers to the last day of that month.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; The active substance is caffeine citrate.<br />Each ml contains 10 mg caffeine citrate (equivalent to 5 mg caffeine).<br />&bull; The other ingredients are citric acid monohydrate, Sodium Chloride, Sodium&nbsp;<br />Hydroxide, Dilute Hydrochloric Acid &amp; water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Biocaffcit 10mg/ml Solution for Injection is a clear, colorless solution for injection. 
Pack size: [10 Glass vials / Pack]
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Pharmaceutical Solutions Industry Ltd.<br />Industrial Estate, Phase-2,&nbsp;<br />Road No. 208, Str. - 203<br />P O Box 17476<br />Jeddah 21484<br />Western Province<br />Saudi Arabia<br />Phone: +966-12-6361383<br />FAX: +966-12-6379460<br />Website: http://www.psiltd.com</p><p><strong>To report any side effect(s):</strong><br />&bull; Saudi Arabia:<br />National Pharmacovigilance and drug safety Center (NPC)<br />Fax: +966-11-2057662<br />Toll free: 8002490000&nbsp;<br />Tel: +966-11-2038222 Ext. 2317-2334-2340 &ndash;2353 &ndash;2354- 2356&nbsp;<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc</p><p><br />Other GCC States:<br />Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                05/2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>الكافيين ينتمى إلى مجموعة من الأدوية تسمى ميثيل زانسينز.<br />- يستخدم في علاج انقطاع النفس عند الأطفال المبتسرين (صعوبات في التنفس نتيجة للولادة قبل الأوان).&nbsp;<br />الفترات القصيرة التي يتوقف فيها الأطفال المبتسرين عن التنفس هى نتيجه لعدم نمو مراكز التنفس لدى الطفل بشكل كامل.&nbsp;<br />لقد تبين أن هذا الدواء يقلل من عدد حالات انقطاع التنفس عند الاطفال المبتسرين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يجب عدم إعطاء طفلك بيوكافست إذا كان لديه حساسية من سترات الكافيين أو لأي من المكونات الأخرى لهذا الدواء&nbsp;<br />المدرجة في القسم ٦<br /><strong>المحاذير والإحتياطات</strong><br />تحدث إلى طبيب طفلك قبل إعطاءه بيوكافست إذا كان طفلك:<br />&bull; يعاني من أمراض الكبد أو الكلى<br />&bull; عدم إنتظام ضربات القلب<br />&bull; يعاني من نوبات&nbsp;<br />&bull; إرتجاع متكرر<br />&bull; زياده معدل التبول أكثر من المعتاد<br />&bull; انخفاض الوزن أو تناول الطعام<br />&bull; إذا كنت (الأم) تتناول الكافيين قبل الولادة<br /><strong>الأدوية الأخرى وبيوكافست</strong><br />ً أو قد يتناول أي أدوية أخرى.<br />أخبر طبيب طفلك إذا كان المولود الجديد يأخذ ، أو أخذ مؤخرا<br />&bull;کما هو الحال مع معظم الأدوية، قد يتفاعل بيوكافست مع الأدوية الأخرى التى يتم تناولها في نفس الوقت، قد يحتاج&nbsp;<br />الطفل المبتسر إلى أدوية كثيرة، وأي مشاكل من الكافيين من المرجح أن تكون طفيفة، ولكن أخبر الطبيب عن أي&nbsp;<br />دواء آخر (على سبيل المثال ثيوفيلين) والذي يعطى لطفلك لمساعدته على التنفس.<br />&bull;الأدوية التي تحتوي على الفينوباربيتون أو الفينيتوين والتي أخذتها الأم نفسها لعلاج الصرع، قد يكون لها أيضا تأثير على&nbsp;<br />طريقة تفاعل الطفل مع العلاج بالكافيين. إذا كنت تتعالجيين من الصرع أثناء الحمل، يرجى إخبار طبيب طفلك بذلك.<br />&bull; دوكسابرام (يستخدم لعلاج صعوبات التنفس)<br />&bull; السيميتيدين (يستخدم لعلاج أمراض المعدة)<br />الكيتوكونازول (يستخدم لعلاج الالتهابات الفطرية)<br />قد يزيد هذا الدواء من إحتماليه الإصابة بأمراض معوية خطيرة مع البراز الدامي (التهاب الأمعاء) عند تناوله مع&nbsp;<br />الأدوية المستخدمة لعلاج أمراض المعدة (مثل حاصرات مستقبلات مضادات الهيستامين ۲H أو مثبطات مضخة&nbsp;<br />البروتون التي تقلل من إفراز حمض المعدة).<br /><strong>الحمل والرضاعة الطبيعية</strong><br />إذا كانت الأم تقوم بالرضاعة الطبيعية لمولودها أثناء علاجه بواسطة بيوكافست، يجب عليها ألا تشرب القهوة أو&nbsp;<br />تأخذ أي منتج آخر يحتوي على نسبة عالية من الكافيين حيث إن الكافيين سينتقل إلى حليب الأم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يجب استخدام محلول بيوكافست فقط في وحدة العناية المركزة لحديثي الولادة حيث تتوفر تسهيلات كافية لمراقبة&nbsp;<br />المرضى ورصدهم. يجب أن يبدأ العلاج تحت إشراف طبيب خبير في العناية المركزة لحديثي الولادة.<br />سيقوم الطبيب أو الممرضة بإعطاء بيوكافست في الوريد (بالتنقيط). ويمكن أيضا أن يعطى عن طريق الفم ويكون فعال&nbsp;<br />بنفس القدر، ويمكن إعطاء كل أو بعض الجرعات بهذه الطريقة عندما يكون ذلك ممكنا. لا ينبغي إعطاء هذا الدواء عن&nbsp;<br />طريق الحقن العضلي.</p><p>تعتمد الجرعة التي يحددها الطبيب على احتياجات كل طفل واستجابته للعلاج، ولكنها عادة ما تكون:<br />الجرعة المبدئيه هي ۲۰ مجم سترات الكافيين لكل كجم من وزن طفلك (أي ما يعادل ۱۰ مجم كافيين لكل كجم أو ۲<br />مل لكل كجم من هذا المحلول) عن طريق الحقن ثم التسريب لمده ۳۰دقيقه.<br />ويتبع ذلك تقليل جرعه المداومة اليومية بعد ۲٤ ساعة من ٥ إلى ۱۰مجم سيترات الكافيين لكل كجم من وزن الطفل&nbsp;<br />(أي ما يعادل ۲٫٥ إلى ٥ مجم كافيين لكل كجم أو۰٫٥ إلى ۱ مل لكل كجم من هذا المحلول )عن طريق الحقن ثم&nbsp;<br />التسريب لمده ۱۰ دقائق.<br />إذا لم يستجب طفلك للجرعة المبدئية (بعد ٤ ساعات على الأقل)، يمكن للطبيب أو الممرضة إعطاء جرعة مبدئية&nbsp;<br />إضافية أخرى، قبل المتابعة عن طريق تقليل جرعات المداومة.</p><p><strong>مدة العلاج</strong><br />سيقوم طبيب طفلك بتحديد فتره علاج طفلك باستخدام بيوكافست. إذا لم يتعرض طفلك لنوبات إنقطاع التنفس لمده ٥<br />إلى ۷ أيام ، فإن الطبيب سيقوم بإيقاف العلاج بواسطه بيوكافست .<br />قد يقرر الطبيب فحص مستويات الكافيين في عينة الدم كإجراء وقائي ، أو إذا كان طفلك لا يستجيب للعلاج كما هو متوقع.<br />ً إذا تم إعطاء طفلك جرعه زائده من بيوكافست عن طريق الخطأ قد تصبح الآثار الجانبية الموضحة أعلاه أكثر وضوحا.&nbsp;<br />ً في حالات الجرعة الزائدة للغاية ، يمكن أن تحدث النوبات أيضا. في حالة ملاحظة علامات الجرعة الزائدة يرجى إخبار&nbsp;<br />طبيب الطفل على الفور.<br />يجب إيقاف العلاج باستخدام بيوكافست على الفور ويجب على طبيب طفلك علاج الجرعة الزائدة.<br />إذا كان لديك أي أسئلة أخرى حول استخدام هذا المنتج الطبي ، اسأل طبيب طفلك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، يمكن أن يسبب هذا الدواء آثارا جانبية، والتي قد لا تظهر على كل شخص يتناول هذا الدواء.<br />ومع ذلك، فإنه من الصعب التمييز بينها وبين المضاعفات المتكررة والتي تحدث في الأطفال المبتسرين والمضاعفات&nbsp;<br />الناجمة عن المرض.<br />أثناء العلاج باستخدام بيوكافست قد يواجه طفلك حديث الولادة بعض الأثار الجانبية التالية:<br /><strong>آثار جانبية خطيرة</strong><br />&bull; مرض معوي خطير مع براز دموي (التهاب الأمعاء التقرحى)<br />&bull; التشنج<br />&bull; الحساسية<br />&bull; عدوى فى الدم (تعفن الدم)<br /><strong>الآثار الجانبية الأخرى</strong><br /><strong>الآثار الجانبية الشائعة (قد تؤثر على ما يصل إلى ۱ من كل ۱۰ أشخاص)</strong><br />&bull; اضطرابات القلب مثل تسارع ضربات القلب&nbsp;<br />&bull; زيادة نسبه السكر بالدم<br /><strong>الآثار الجانبية الغير شائعة (قد تؤثر على ما يصل إلى ۱ من كل ۱۰۰ شخص)</strong><br />&bull; اضطرابات القلب مثل عدم انتظام ضربات القلب&nbsp;<br />الآثار الجانبية التي لا يمكن تقدير معدل حدوثها من البيانات المتاحة<br />&bull; انخفاض السكر في الدم أو المصل (نقص السكر في الدم)<br />&bull; عدم النمو<br />&bull; عدم تحمل الطعام&nbsp;<br />&bull; تحفيز الجهاز العصبي المركزي مثل التهيج<br />&bull; العصبية والأرق<br />&bull; إصابة الدماغ<br />&bull; الصمم<br />&bull; ارتجاع<br />&bull; زيادة في نضح المعدة<br />&bull; زيادة تدفق البول<br />&bull; زيادة بعض مكونات البول (الصوديوم والكالسيوم)<br />&bull; تغييرات في اختبارات الدم (انخفاض مستويات الهيموجلوبين بعد العلاج لفترات طويلة)<br />&bull; انخفاض هرمون الغدة الدرقية في بداية العلاج<br /><strong>الإبلاغ عن الآثار الجانبية</strong><br />إذا حدث لطفلك أي آثار جانبية، تحدث مع طبيب طفلك. وهذا يشمل أي آثار جانبية محتملة غير مدرجة في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ هذا الدواء بعيدا عن مرأى و متناول الأطفال.<br />لا تحفظ الدواء فى درجه حراره تزيد عن ۳۰ درجة مئوية.<br />يجب فحص جميع المحاليل الوريدية بصريا بحثا عن الجسيمات الصغيرة قبل إستخدامها ، يجب استخدام بيوكافست&nbsp;<br />فورا بعد فتح الـڤيال.<br />في حالة التخفيف، يمكن حفظ المحلول المخفف فى درجة حرارة الغرفة لمدة ٤ ساعات.<br />لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على الملصق. أوإذا كان هناك أي علامات على تغير لون المحلول.<br />يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>بيوكافست يحتوي على<br />&bull; المادة الفعالة هي سترات الكافيين.<br />كل مل يحتوي على ۱۰ مجم سترات الكافيين (أي ما يعادل ٥ مجم كافيين)</p><p>&bull; المكونات الأخرى : حامض الستريك أحادى التميؤ ، صوديوم كلوريد ، صوديوم هيدروكسيد، حامض&nbsp;<br />الهيدروكلوريك المخفف ،&nbsp;<br />ماء معد للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>بيوكافست هو محلول مائي شفاف ، عديم اللون يستخدم عن طريق الحقن الوريدي<br />محتوي العبوة : ۱۰ فيال زجاجية فى العبوة الخارجية.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>مصنع المحاليل الطبية.<br />العنوان:المنطقة الصناعية، المرحلة الثانية.<br />طريق رقم ،۲۰۸ شارع ۲۰۳<br />صندوق بريد ۱۷٤۷٦ جدة .۲۱٤۸٤<br />المنطقة الغربية<br />المملكة العربية السعودية<br />الهاتف: +۹٦٦-۱۲-٦۳٦۱۳۸۳<br />الفاكس: +۹٦٦-۱۲-٦۳۷۹٤٦۰<br />http://www.psiltd.com :الاليكتروني الموقع</p><p><br />للإبلاغ عن أي أعراض جانبیة:</p><p><br />المملكة العربیة السعودیة<br />المركز الوطني للتیقظ والسلامة الدوائیة&nbsp;<br />فاكس+۹٦٦۱۱۲۰٥۷٦٦۲:&nbsp;<br />ھاتف مجاني: ۸۰۰۲٤۹۰۰۰۰<br />تلفون: ۰۰۹٦٦-۱۱-۲۰۳۸۲۲۲<br />تحویلة: ،۲۳٥۳ ،۲۳٥٦ ،۲۳۱۷ ،۲۳٥٤ ،۲۳۳٤ ۲۳٤۰<br />npc.drug@sfda.gov.sa : الألكتروني البرید<br />www.sfda.gov.sa/npc : الألكتروني الموقع</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            05/2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Biocaffcit 
 “Caffeine Citrate 10mg/ml Solution for Injection”
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Caffeine Citrate 10mg/ml
Each 1ml of solution contains, 10mg Caffeine Citrate, equivalent to 5mg of Caffeine.
Each 2ml of solution contains, 20mg Caffeine Citrate, equivalent to 10mg of Caffeine.
Excipient(s) with known effect
1ml of the solution contains 3.04mg sodium
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dose of Biocaffcit 
10mg/ml Solution 
for Injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of apnoea of prematurity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>4.2 Posology and method of administration<br />Treatment with caffeine citrate should be initiated under the supervision of a physician&nbsp;<br />experienced in neonatal intensive care. Treatment should be administered only in a&nbsp;<br />neonatal intensive care unit in which adequate facilities are available for patient&nbsp;<br />surveillance and monitoring.</p><p>Posology<br />The recommended doses of Biocaffcit 10mg/ml Solution for Injection are expressed&nbsp;<br />below. Please note:<br />(a) The dose expressed as caffeine citrate is twice the dose expressed as caffeine base.<br />(b) Given orally or intravenously, caffeine is clinically effective within 4 hours. If the&nbsp;<br />patient fails to respond within this time, a second loading dose may be given. If there is&nbsp;<br />no clinical response to the second loading dose, caffeine blood levels should be measured&nbsp;<br />(see &#39;special warnings and precautions for use&#39; section 4.4 below)<br />(c) Biocaffcit 10mg/ml Solution for Injection is also effective when administered orally,&nbsp;<br />and this route may be used alternatively without adjusting the dose.<br />(d) Because of the slow elimination of caffeine in this patient population, there is no&nbsp;<br />requirement for dose tapering on cessation of treatment.<br />(e) Infants must be of sufficient respiratory maturity not to require positive pressure&nbsp;<br />ventilation.</p><table border="1" cellspacing="1" cellpadding="1" style="width:698px"><tbody><tr><td style="width:169px">&nbsp;</td><td style="width:220px">Dose of Biocaffcit 10mg/ml Solution for Injection</td><td style="width:97px">Dose Expressed as Caffeine Citrate</td><td style="width:60px">Dose Expressed as Caffeine Base</td><td style="width:114px">Route</td><td style="width:87px">Frequency</td></tr><tr><td style="width:169px">Loading Dose See (b) above</td><td style="width:220px">2ml/kg</td><td style="width:97px">20 mg/kg</td><td style="width:60px">10mg/kg</td><td style="width:114px">Intravenous** (over 30 min) or oral</td><td style="width:87px">Once</td></tr><tr><td style="width:169px">Maintenance Dose</td><td style="width:220px">0.5-1ml/kg*</td><td style="width:97px">5-10mg/kg*</td><td style="width:60px">2.5-5.0mg/kg*</td><td style="width:114px">Intravenous** (over 10 min) or oral</td><td style="width:87px">Every 24 hours***</td></tr></tbody></table><p>* In some cases maintenance doses higher than 10mg/kg/day (expressed as caffeine&nbsp;<br />citrate) may be required to achieve maximal efficacy (eg in continuing apnoeic episodes&nbsp;<br />where plasma levels indicate the dose may be safely increased)<br />** By intravenous infusion<br />*** Beginning 24 hours after the loading dose(s)</p><p><br /><strong>Dosage, adjustments and monitoring</strong><br />Plasma concentrations of caffeine may need to be monitored periodically throughout&nbsp;<br />treatment in cases of incomplete clinical response or signs of toxicity.<br />Additionally, doses may need to be adjusted according to medical judgment following&nbsp;<br />routine monitoring of caffeine plasma concentrations in at risk situations such as:<br />- very premature infants (&lt; 28 weeks gestational age and/or body weight &lt;1000 g)&nbsp;<br />particularly when receiving parenteral nutrition<br />- infants with hepatic and renal impairment (see sections 4.4 and 5.2)<br />- infants with seizure disorders<br />- infants with known and clinically significant cardiac disease<br />- infants receiving co-administration of medicinal products known to interfere with&nbsp;<br />caffeine metabolism (see section 4.5)<br />- infants whose mothers consume caffeine while providing breast milk for feeding.<br />It is advisable to measure baseline caffeine levels in:<br />- infants whose mothers may have ingested large quantities of caffeine prior to delivery&nbsp;<br />(see section 4.4)</p><p>- infants who have previously been treated with theophylline, which is metabolized to&nbsp;<br />caffeine.<br />Caffeine has a prolonged half-life in premature newborn infants and there is potential for&nbsp;<br />accumulation which may necessitate monitoring infants treated for an extended period&nbsp;<br />(see section 5.2). Blood samples for monitoring should be taken just before the next dose&nbsp;<br />in the case of therapeutic failure and 2 to 4 hours after the previous dose when suspecting&nbsp;<br />toxicity.<br />Although a therapeutic plasma concentration range of caffeine has not been determined in&nbsp;<br />the literature, caffeine levels in studies associated with clinical benefit ranged from 8 to&nbsp;<br />30 mg/l and no safety concerns have normally been raised with plasma levels below 50&nbsp;<br />mg/l.<br />&nbsp;</p><p><strong>Duration of treatment</strong><br />The optimal duration of treatment has not been established. In a recent large multicentre&nbsp;<br />study on preterm newborn infants a median treatment period of 37 days was reported.<br />Treatment should be continued until the child has reached a gestational age of 37 weeks,&nbsp;<br />by which time apnoea of prematurity usually resolves spontaneously. This limit may&nbsp;<br />however be revised according to clinical judgement in individual cases depending on&nbsp;<br />response to treatment, the continuing presence of apnoeic episodes despite treatment, or&nbsp;<br />other clinical considerations.<br />Please see Section 4.4 below regarding use of the filter straws.<br />It is recommended that caffeine citrate administration should be stopped when the patient&nbsp;<br />has 5-7 days without a significant apnoeic attack. If the patient has recurrent apnoea,&nbsp;<br />caffeine citrate administration can be restarted with either a maintenance dose or a half&nbsp;<br />loading dose, depending upon the time interval from stopping caffeine citrate to&nbsp;<br />recurrence of apnoea.<br />Because of the slow elimination of caffeine in this patient population, there is no&nbsp;<br />requirement for dose tapering on cessation of treatment.<br />As there is a risk for recurrence of apnoeas after cessation of caffeine citrate treatment&nbsp;<br />monitoring of the patient should be continued for approximately one week.</p><p><strong>Hepatic and renal impairment</strong><br />There is limited experience in patients with renal and hepatic impairment. In a post&nbsp;<br />authorisation safety study, the frequency of adverse reactions in a small number of very&nbsp;<br />premature infants with renal/hepatic impairment appeared to be higher as compared to&nbsp;<br />premature infants without organ impairment (see sections 4.4 and 4.8).<br />In the presence of renal impairment, a reduced daily maintenance dose of caffeine is&nbsp;<br />required and the dose should be guided by blood caffeine measurements. There is&nbsp;<br />increased potential for accumulation.<br />In very premature infants, clearance of caffeine does not depend on hepatic function.&nbsp;<br />Hepatic caffeine metabolism develops progressively in the weeks following birth and for&nbsp;the older infant, hepatic disease may indicate a need for monitoring plasma levels and&nbsp;<br />may require dose adjustments (see sections 4.4 and 5.2).<br /><strong>Adults and Children</strong><br />Not applicable<br /><strong>Elderly</strong><br />Not applicable</p><p><br /><strong>Method of administration</strong><br />Biocaffcit 10mg/ml Injection should not be given intramuscularly; being acidic, i.m.&nbsp;<br />injection is likely to be painful. When given intravenously, it should be given as a slow&nbsp;<br />infusion rather than a bolus injection; there is evidence that bolus administration may&nbsp;<br />cause sudden changes in blood pressure.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to caffeine citrate or to any of the excipients listed in section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Apnoea<br />Apnoea of prematurity is a diagnosis of exclusion. Other causes of apnoea (e.g., central&nbsp;<br />nervous system disorders, primary lung disease, anemia, sepsis, metabolic disturbances,&nbsp;<br />cardiovascular abnormalities, or obstructive apnoea) should be ruled out or properly&nbsp;<br />treated prior to initiation of treatment with caffeine citrate.<br />It is advisable to monitor plasma levels of caffeine periodically. However, at the&nbsp;<br />recommended doses, frequent (more than weekly) monitoring of plasma levels is not&nbsp;<br />normally necessary unless there are concerns regarding lack of efficacy or possible&nbsp;<br />toxicity. In premature neonates, caffeine has a prolonged half-life. If higher maintenance&nbsp;<br />dosages are used, the clinician should recognize this potential for accumulation and&nbsp;<br />monitor plasma caffeine levels (see also Section 5.2).<br />If there is inadequate clinical response to the first loading dose, a second dose may be&nbsp;<br />given, but if there is continued inadequate response, the plasma levels should be&nbsp;<br />confirmed before further doses are given, as the failure to respond could be an indication&nbsp;<br />of another cause of apnoea. Plasma levels should not normally exceed 50micrograms/ml&nbsp;<br />(optimally 10-30micrograms/ml).<br />Caffeine consumption<br />In newborn infants born to mothers who consumed large quantities of caffeine prior to&nbsp;<br />delivery, baseline plasma caffeine concentrations should be measured prior to initiation&nbsp;<br />of treatment with caffeine citrate, since caffeine readily crosses the placenta into the&nbsp;<br />foetal circulation (see sections 4.2 and 5.2).<br />Breast-feeding mothers of newborn infants treated with caffeine citrate should not ingest&nbsp;<br />caffeine-containing foods and beverages or medicinal products containing caffeine (see&nbsp;<br />section 4.6), since caffeine is excreted into breast milk (see section 5.2).<br />Theophylline<br />In newborns previously treated with theophylline, baseline plasma caffeine&nbsp;<br />concentrations should be measured prior to initiation of treatment with caffeine citrate&nbsp;<br />because preterm infants metabolise theophylline to caffeine.<br />Seizures<br />Caffeine is a central nervous system stimulant and seizures have been reported in cases of&nbsp;<br />caffeine overdose. Extreme caution must be exercised if caffeine citrate is used in&nbsp;<br />newborns with seizure disorders.<br />Cardiovascular reactions<br />Caffeine has been shown to increase heart rate, left ventricular output, and stroke volume&nbsp;<br />in published studies. Therefore, caffeine citrate should be used with caution in newborns&nbsp;<br />with known cardiovascular disease. There is evidence that caffeine causes&nbsp;<br />tachyarrhythmias in susceptible individuals. In newborns this is usually a simple sinus&nbsp;<br />tachycardia. If there have been any unusual rhythm disturbances on a cardiotocograph&nbsp;<br />(CTG) trace before the baby is born, caffeine citrate should be administered with caution.<br />Renal and hepatic impairment<br />Caffeine citrate should be administered with caution in preterm newborn infants with&nbsp;<br />impaired renal or hepatic function. In a post-authorisation safety study, the frequency of&nbsp;<br />adverse reactions in a small number of very premature infants with renal/hepatic&nbsp;<br />impairment appeared to be higher as compared to premature infants without organ&nbsp;<br />impairment (see sections 4.2, 4.8 and 5.2). Doses should be adjusted by monitoring of&nbsp;<br />caffeine plasma concentrations to avoid toxicity in this population.<br />Necrotising enterocolitis<br />Necrotising enterocolitis is a common cause of morbidity and mortality in premature&nbsp;<br />newborn infants. There are reports of a possible association between the use of&nbsp;<br />methylxanthines and development of necrotising enterocolitis. However, a causal&nbsp;<br />relationship between caffeine or other methylxanthine use and necrotising enterocolitis&nbsp;<br />has not been established. As for all preterm infants, those treated with caffeine citrate&nbsp;<br />should be carefully monitored for the development of necrotising enterocolitis (see&nbsp;<br />section 4.8).<br />Caffeine citrate should be used with caution in infants suffering gastro-oesophageal&nbsp;<br />reflux, as the treatment may exacerbate this condition.<br />Caffeine citrate causes a generalised increase in metabolism, which may result in higher&nbsp;<br />energy and nutrition requirements during therapy.<br />The diuresis and electrolyte loss induced by caffeine citrate may necessitate correction of&nbsp;<br />fluid and electrolyte disturbances.<br />Use of filter straws<br />Opening the vial may introduce glass particles into this solution. It is recommended that&nbsp;<br />the solution be filtered prior to use by means of a suitable filter device.<br />Biocaffcit 10mg/ml Injection contains sodium<br />This medicinal product contains 3.04mg sodium per 1ml of the solution. To be taken into&nbsp;<br />consideration by patients on a controlled sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cytochrome P450 1A2 (CYP1A2) is the major enzyme involved in the metabolism of&nbsp;<br />caffeine in humans. Therefore, caffeine has the potential to interact with active&nbsp;<br />substances that are substrates for CYP1A2, inhibit CYP1A2, or induce CYP1A2.&nbsp;<br />However, caffeine metabolism in preterm newborn infants is limited due to their&nbsp;<br />immature hepatic enzyme systems.<br />Interconversion between caffeine and other xanthines such as theophylline has been&nbsp;<br />reported in premature neonates. Therefore the concurrent use of these drugs should be&nbsp;<br />avoided. Baseline serum levels of caffeine should be measured in patients previously&nbsp;<br />treated with theophylline.<br />Although few data exist on interactions of caffeine with other active substances in&nbsp;<br />preterm newborn infants, lower doses of caffeine citrate may be needed following coadministration of active substances which are reported to decrease caffeine elimination in&nbsp;<br />adults (e.g., cimetidine and ketoconazole) and higher caffeine citrate doses may be&nbsp;<br />needed following co-administration of active substances that increase caffeine&nbsp;<br />elimination (e.g., phenobarbital and phenytoin). Where doubt exists about possible&nbsp;<br />interactions, plasma caffeine concentrations should be measured.<br />As bacterial overgrowth in the gut is associated with the development of necrotising&nbsp;<br />enterocolitis, co-administration of caffeine citrate with medicinal products that suppress&nbsp;<br />gastric acid secretion (antihistamine H2 receptor blockers or proton-pump inhibitors) may&nbsp;<br />in theory increase the risk of necrotising enterocolitis (see section 4.4 and 4.8).<br />Concurrent use of caffeine and doxapram might potentiate their stimulatory effects on the&nbsp;<br />cardio-respiratory and central nervous system. If concurrent use is indicated, cardiac&nbsp;<br />rhythm and blood pressure must be carefully monitored.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Fertility</strong></p><p>Effects on reproductive performance observed in animals are not relevant to its indication&nbsp;<br />in the preterm newborn infants (see section 5.3).</p><p><strong>Pregnancy</strong><br />Caffeine in animal studies, at high doses, was shown to be embryotoxic and teratogenic.&nbsp;<br />These effects are not relevant with regard to short term administration in the preterm&nbsp;<br />infant population (see section 5.3).</p><p><strong>Breast-feeding</strong><br />Caffeine is excreted into breast milk and readily crosses the placenta into the foetal&nbsp;<br />circulation (see section 5.2).<br />Breast-feeding mothers of newborn infants treated with caffeine citrate should not ingest&nbsp;<br />caffeine-containing foods, beverages or medicinal products containing caffeine.<br />In newborn infants born to mothers who consumed large quantities of caffeine prior to&nbsp;<br />delivery, baseline plasma caffeine concentrations should be measured prior to initiation&nbsp;<br />of treatment with caffeine citrate (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Summary of the safety profile</strong><br />The known pharmacology and toxicology of caffeine and other methylxanthines predict&nbsp;<br />the likely adverse reactions to caffeine citrate. Effects described include central nervous<br />system (CNS) stimulation such as convulsion, irritability, restlessness and jitteriness,&nbsp;<br />cardiac effects such as tachycardia, arrhythmia, hypertension and increased stroke&nbsp;<br />volume, metabolism and nutrition disorders such as hyperglycaemia. These effects are&nbsp;<br />dose related and may necessitate measurement of plasma levels and dose reduction.<br />They are generally, although not exclusively, associated with serum caffeine&nbsp;<br />concentrations &ge;50micrograms/ml.</p><p>Tabulated list of adverse reactions<br />The adverse reactions described in the short- and long-term published literature and&nbsp;<br />obtained from a post-authorisation safety study that can be associated with caffeine&nbsp;<br />citrate are listed below by System Organ Class and Preferred Term (MedDRA).<br />Frequency is defined as: very common (&ge; 1/10), common (&ge;1/100 to &lt; 1/10), uncommon&nbsp;<br />(&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000) and not&nbsp;<br />known (cannot be estimated from the available data).</p><table border="1" cellspacing="1" cellpadding="1" style="width:728px"><tbody><tr><td style="width:201px">System Organ Class</td><td style="width:265px">Adverse Reaction</td><td style="width:256px">Frequency</td></tr><tr><td style="width:201px">Infections and infestations</td><td style="width:265px">Sepsis</td><td style="width:256px">Not known</td></tr><tr><td style="width:201px">Immune system disorders</td><td style="width:265px">Hypersensitivity reaction</td><td style="width:256px">Rare</td></tr><tr><td style="width:201px">Metabolism and nutrition disorders</td><td style="width:265px"><p>Hyperglycaemia</p><p>Hypoglycaemia, failure to thrive, feeding intolerance</p></td><td style="width:256px"><p>Common</p><p>Not known</p></td></tr><tr><td style="width:201px">Nervous system disorders</td><td style="width:265px"><p>Convulsion</p><p>Irritability, jitteriness, restlessness, brain injury</p></td><td style="width:256px"><p>Uncommon</p><p>Not known</p></td></tr><tr><td style="width:201px">Ear and labyrinth disorders</td><td style="width:265px">Deafness</td><td style="width:256px">Not known</td></tr><tr><td style="width:201px">Cardiac disorders</td><td style="width:265px"><p>Tachycardia</p><p>Arrhythmia</p><p>Increased left ventricular output and increased stroke volume</p></td><td style="width:256px"><p>Common</p><p>Uncommon</p><p>Not known</p></td></tr><tr><td style="width:201px">Gastrointestinal disorders</td><td style="width:265px">Regurgitation, increased gastric aspirate, necrotising enterocolitis</td><td style="width:256px">Not known</td></tr><tr><td style="width:201px">General disorders and</td><td style="width:265px">Infusion site phlebitis, infusion site</td><td style="width:256px">Common</td></tr><tr><td style="width:201px">administration site conditions</td><td style="width:265px">inflammation</td><td style="width:256px">&nbsp;</td></tr><tr><td style="width:201px">Investigations</td><td style="width:265px">Urine output increased, urine sodium and calcium increased, haemoglobin decreased, thyroxine decreased</td><td style="width:256px">Not known</td></tr></tbody></table><p><strong>Description of selected adverse reactions</strong><br />Necrotising enterocolitis is a common cause of morbidity and mortality in premature&nbsp;<br />newborn infants. There are reports of a possible association between the use of&nbsp;<br />methylxanthines and development of necrotising enterocolitis. However, a causal&nbsp;<br />relationship between caffeine or other methylxanthine use and necrotising enterocolitis&nbsp;<br />has not been established.<br />In a double-blind placebo-controlled study of caffeine citrate in 85 preterm infants (see&nbsp;<br />section 5.1), necrotising enterocolitis was diagnosed in the blinded phase of the study in&nbsp;<br />two infants on active treatment and one on placebo, and in three infants on caffeine&nbsp;<br />during the open-label phase of the study. Three of the infants who developed necrotising&nbsp;<br />enterocolitis during the study died. A large multicentre study (n=2006) investigating&nbsp;<br />long-term outcome of premature infants treated with caffeine citrate (see section 5.1) did&nbsp;<br />not show an increased frequency of necrotising enterocolitis in the caffeine group when&nbsp;<br />compared to placebo. As for all preterm infants, those treated with caffeine citrate should&nbsp;<br />be carefully monitored for the development of necrotising enterocolitis (see section 4.4).&nbsp;<br />Brain injury, convulsion and deafness were observed but they were more frequent in the&nbsp;<br />placebo group.<br />Caffeine may suppress erythropoietin synthesis and hence reduce haemoglobin&nbsp;<br />concentration with prolonged treatment.<br />Transient falls in thyroxine (T4) have been recorded in infants at the start of therapy but&nbsp;<br />these are not sustained with maintained therapy.<br />Available evidence does not indicate any adverse long-term reactions of neonatal caffeine&nbsp;<br />therapy as regards neurodevelopmental outcome, failure to thrive or on the&nbsp;<br />cardiovascular, gastrointestinal or endocrine systems. Caffeine does not appear to&nbsp;<br />aggravate cerebral hypoxia or to exacerbate any resulting damage, although the&nbsp;<br />possibility cannot be ruled out.<br /><strong>Other special populations</strong><br />In a post-authorisation safety study on 506 preterm infants treated with Peyona, safety&nbsp;<br />data have been collected in 31 very premature infants with renal/hepatic impairment.&nbsp;<br />Adverse reactions appeared to be more frequent in this subgroup with organ impairment&nbsp;<br />than in other observed infants without organ impairment. Cardiac disorders (tachycardia,&nbsp;<br />including one single case of arrhythmia) were mostly reported.</p><p>To report any side effect(s):<br />Saudi Arabia:<br />The National Pharmacovigilance and Drug Safety Centre (NPC)&nbsp;<br />&nbsp;Fax: +966-11-205-7662&nbsp;<br />&nbsp;Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.&nbsp;<br />&nbsp;Toll free phone: 8002490000&nbsp;<br />&nbsp;E-mail: npc.drug@sfda.gov.sa&nbsp;<br />&nbsp;Website: www.sfda.gov.sa/npc</p><p>Other GCC States:&nbsp;<br />Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Following overdose, published plasma caffeine levels have ranged from approximately&nbsp;<br />50 mg/l to 350 mg/l.<br /><u><strong>Symptoms</strong></u><br />Signs and symptoms of overdosage from these reports include jitteriness, tachycardia,&nbsp;<br />tachypnoea, tremor, opisthotonos, rigidity and tonic-clonic movements, hypokalaemia, ,&nbsp;<br />restlessness, , gastric irritation, gastro-intestinal haemorrhage, increased white blood cell&nbsp;<br />count, non-purposeful jaw and lip movements. One case of caffeine overdose&nbsp;<br />complicated by development of intraventricular haemorrhage and long-term neurological&nbsp;<br />sequelae has been reported. In one case of overdose the patient developed compromised&nbsp;<br />circulation, vomiting and seizures. Other reported effects of gross overdose include fever,&nbsp;<br />agitation, hyperexcitability, hypertonia, gastric residues, distended abdomen, metabolic&nbsp;<br />acidosis, hyperglycaemia and elevated urea levels. No deaths associated with caffeine&nbsp;<br />overdose have been reported in preterm infants.<br /><u><strong>Management</strong></u><br />Treatment of overdosage should include monitoring of blood levels of caffeine and&nbsp;<br />supportive measures. Plasma potassium and glucose concentrations should be monitored&nbsp;<br />and hypokalaemia and hyperglycaemia corrected.<br />Previous cases reported resolved satisfactorily.<br />In severe cases of overdose, exchange transfusion should be considered. In one case, this&nbsp;<br />was found to reduce plasma caffeine levels by 40mg/L per transfusion.<br />Convulsions may be treated with intravenous administration of anticonvulsants&nbsp;<br />(diazepam or a barbiturate such as pentobarbital sodium or phenobarbital).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Psychoanaleptics xanthine derivatives<br />ATC code: N06BC01<br />Mechanism of action<br />Caffeine is structurally related to the methylxanthines theophylline and theobromine.&nbsp;<br />Most of its effects have been attributed to antagonism of adenosine receptors, both&nbsp;<br />A1 and A2A subtypes, demonstrated in receptor binding assays and observed at&nbsp;<br />concentrations approximating those achieved therapeutically in this indication.<br />Pharmacodynamic effects<br />The desired respirogenic activity of caffeine is an expression of its central nervous&nbsp;<br />system stimulation, although it may also increase the sensitivity of respiratory response to&nbsp;<br />carbon dioxide levels. Caffeine increases both tidal volume and frequency of ventilation.<br />In the premature infant, caffeine produced increased minute ventilation, mainly due to an&nbsp;<br />increase in inspiratory drive as shown by an increased mean respiratory flow (V&Tau;/T1).&nbsp;<br />Caffeine regularises the breathing pattern, indicating that it stabilises the oscillation of the&nbsp;<br />respiratory control system.<br />Caffeine also inhibits phosphodiesterase, but this effect only occurs at concentrations&nbsp;<br />associated with toxicity, and not at therapeutic concentrations.<br />Caffeine increases metabolic rate, heart rate, cardiac contractility and output. It also&nbsp;<br />increases blood flow to the kidneys, and prevents sodium and chloride from reabsorbing&nbsp;<br />at the proximal tubules, so mild diuresis can occur.<br />Adenosine is a vasodilator and therefore caffeine, as its antagonist, can cause&nbsp;<br />vasoconstriction. Hence it is a vasoconstrictor in the cerebral and splanchnic circulations.&nbsp;<br />Elsewhere, it has a vasodilator effect due to an effect on vascular smooth muscle.<br />The stimulant effect may affect sleep patterns.<br />Clinical efficacy and safety<br />The clinical efficacy of caffeine citrate was assessed in a multicentre, randomised,&nbsp;<br />double-blind study that compared caffeine citrate to placebo in 85 preterm infants&nbsp;<br />(gestational age 28 to &lt; 33 weeks) with apnoea of prematurity. Infants received 20 mg/kg&nbsp;<br />caffeine citrate loading dose intravenously. A maintenance daily dose of 5 mg/kg caffeine&nbsp;<br />citrate was then administered either intravenously or orally (through a feeding tube) for&nbsp;<br />up to 10-12 days. The protocol allowed infants to be &ldquo;rescued&rdquo; with open-label caffeine&nbsp;<br />citrate treatment if their apnoea remained uncontrolled. In that case, infants received a&nbsp;<br />second loading dose of 20 mg/kg caffeine citrate after treatment day 1 and before&nbsp;<br />treatment day 8.<br />There were more days without any apnoea under caffeine citrate treatment (3.0 days,&nbsp;<br />versus 1.2 days for placebo; p=0.005); also, there was a higher percentage of patients&nbsp;<br />with no apnoeas for &gt; 8 days (caffeine 22% versus placebo 0%).<br />A recent large placebo-controlled multicentre study (n=2006) investigated short-term and&nbsp;<br />long-term (18-21 months) outcomes of premature infants treated with caffeine citrate.&nbsp;<br />Infants randomised to caffeine citrate received an intravenous loading dose of 20 mg/kg,&nbsp;<br />followed by a daily maintenance dose of 5 mg/kg. If apnoeas persisted, the daily maintenance dose could be increased to a maximum of 10 mg/kg of caffeine citrate. The&nbsp;<br />maintenance doses were adjusted weekly for changes in body weight and could be given&nbsp;<br />orally once an infant tolerated full enteral feedings. Caffeine therapy reduced the rate of&nbsp;<br />bronchopulmonary dysplasia [odds ratio (95%CI) 0.63 (0.52 to 0-76)] and improved the&nbsp;<br />rate of survival without neurodevelopmental disability [odds ratio (95%CI) 0.77 (0.64 to&nbsp;<br />0.93)].<br />The size and direction of caffeine effect on death and disability differed depending on the&nbsp;<br />degree of respiratory support infants needed at randomisation, indicating more benefit for&nbsp;<br />the supported infants [odds ratio (95%CI) for death and disability, see table below].<br />Death or disability according to subgroup of respiratory support at entry to study</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td>Subgroups</td><td>Odds ratio (95% CI)</td></tr><tr><td>No support</td><td>1.32 (0.81 to 2.14)</td></tr><tr><td>Non invasive support</td><td>0.73 (0.52 to 1.03)</td></tr><tr><td>Endotracheal tube</td><td>0.73 (0.57 to 0.94)</td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Caffeine citrate readily dissociates in aqueous solution. The citrate moiety is rapidly&nbsp;<br />metabolized on infusion or ingestion.<br /><strong>Absorption</strong><br />The onset of action of caffeine from caffeine citrate is within minutes of commencement&nbsp;<br />of infusion. In neonates, orally administered caffeine has been shown to be rapidly and&nbsp;<br />completely absorbed. After oral administration of 10 mg caffeine base/kg body weight to&nbsp;<br />preterm newborn infants, the peak plasma caffeine concentration (Cmax) ranged from 6 to&nbsp;<br />10 mg/l and the mean time to reach peak concentration (tmax) ranged from 30 min to 2 h.&nbsp;<br />The extent of absorption is not affected by formula feeding but tmax may be prolonged.<br /><strong>Distribution</strong><br />Caffeine is rapidly distributed into the brain following caffeine citrate administration.&nbsp;<br />Caffeine concentrations in the cerebrospinal fluid of preterm newborn infants&nbsp;<br />approximate to their plasma levels. The mean volume of distribution (Vd) of caffeine in&nbsp;<br />infants (0.8-0.9 l/kg) is slightly higher than that in adults (0.6 L/kg). Plasma protein&nbsp;<br />binding data are not available for newborn infants or infants. In adults, the mean plasma&nbsp;<br />protein binding in vitro is reported to be approximately 36%.<br />Caffeine readily crosses the placenta into the fetal circulation and is excreted into breast&nbsp;<br />milk.<br /><strong>Biotransformation</strong><br />Caffeine metabolism in preterm newborn infants is very limited due to their immature&nbsp;<br />hepatic enzyme systems and most of the active substance is eliminated in urine. Hepatic&nbsp;<br />cytochrome P450 1A2 (CYP1A2) is involved in caffeine biotransformation in older&nbsp;<br />individuals.<br />Inter-conversion between caffeine and theophylline has been reported in preterm&nbsp;<br />newborn infants; caffeine levels are approximately 25% of theophylline levels after theophylline administration and approximately 3-8% of caffeine administered would be&nbsp;<br />expected to convert to theophylline.</p><p><strong>Elimination</strong><br />In young infants, the elimination of caffeine is much slower than that in adults due to&nbsp;<br />immature hepatic and/or renal function. In newborn infants, caffeine clearance is almost&nbsp;<br />entirely by renal excretion. Mean half-life (t1/2) and fraction excreted unchanged in urine&nbsp;<br />(Ae) of caffeine in infants are inversely related to gestational / postmenstrual age. In&nbsp;<br />newborn infants, the t1/2 is approximately 3-4 days and the Ae is approximately 86%&nbsp;<br />(within 6 days). By 9 months of age, the metabolism of caffeine approximates to that&nbsp;<br />seen in adults (t1/2 = 5 hours and Ae = 1%).<br />Studies examining the pharmacokinetics of caffeine in newborn infants with hepatic or&nbsp;<br />renal insufficiency have not been conducted.<br />In the presence of significant renal impairment, considering the increased potential for&nbsp;<br />accumulation, a reduced daily maintenance dose of caffeine is required and the doses&nbsp;<br />should be guided by blood caffeine measurements. In premature infants with cholestatic&nbsp;<br />hepatitis a prolonged caffeine elimination half-life with an increase of plasma levels&nbsp;<br />above the normal limit of variation has been found suggesting a particular caution in the&nbsp;<br />dosage of these patients (see sections 4.2 and 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non- clinical data revealed no major hazard for humans based on studies of repeated dose&nbsp;<br />toxicity of caffeine. However, at high doses convulsions in rodents were induced. At&nbsp;<br />therapeutic doses some behavioural changes in newborn rats were induced, most likely as&nbsp;<br />a consequence of increased adenosine receptor expression that persisted into adulthood.&nbsp;<br />Caffeine was shown to be devoid of mutagenic and oncogenic risk. Teratogenic potential&nbsp;<br />and effects on reproductive performance observed in animals are not relevant to its&nbsp;<br />indication in the preterm infant population.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>- Sodium Chloride : 7.725 mg/ml<br />- Citric acid monohydrate : 5.47 mg/ml<br />- Sodium Hydroxide : Q.S.<br />- Dilute Hydrochloric Acid : Q.S.<br />- Water For Injections to 1 ml</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products except those&nbsp;<br />mentioned in section 6.6</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
After opening the vial, the medicinal product should be used immediately.
After dilution, the diluted solution could be stored at room temperature for 4 hours.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.&nbsp;<br />For storage conditions of the diluted medicinal product see section 6.3.<br />No special precautions are required for storage.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Type I clear glass Vial containing 1ml or 2ml Solution<br />Pack size: [10 Glass vials / Pack]</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Only clear solution without particulate matter should be used. For single use only. Any&nbsp;<br />unused solution should be discarded.<br />There was no detectable degradation of the solution when diluted 50/50 with commercial&nbsp;<br />glucose 5%, glucose 4% saline 0.18%, and sodium chloride 0.9% infusions, when stored&nbsp;<br />in disposable plastic syringes at room temperature for 4 hours.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pharmaceutical Solutions Industry Ltd.
Industrial Estate, Phase-2, 
Road No. 208, Str. - 203
P O Box 17476
Jeddah 21484
Western Province
Saudi Arabia
Phone: +966-12-6361383
FAX: +966-12-6379460
Website: http://www.psiltd.com

To report any side effect(s):

For Saudi Arabia:

The National Pharmacovigilance and Drug Safety Centre (NPC)

* Fax: +966-11-205-7662

* Reporting hotline: 19999.

* E-mail: npc.drug@sfda.gov.sa

* Website: www.sfda.gov.sa/npc

Other GCC States:
Please contact the relevant competent authority
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                05/2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>